Key Points Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its losses have been rising in recent years as has its share count -- a notable concern for investors. 10 stocks we like better than Recursion Pharmaceuticals › Artificial intelligence (AI) has the potential to transform all sectors and industries throughout the economy. Investing in companies th ...